QQQ   347.72 (-0.65%)
AAPL   178.56 (+0.71%)
MSFT   329.60 (-0.49%)
META   262.38 (-0.05%)
GOOGL   122.82 (-0.69%)
AMZN   119.97 (-1.39%)
TSLA   199.33 (-0.91%)
NVDA   382.94 (-4.53%)
NIO   7.41 (+0.00%)
BABA   79.40 (+0.93%)
AMD   119.67 (-4.47%)
T   15.78 (+0.90%)
F   12.03 (-4.45%)
MU   68.29 (-4.74%)
CGC   0.82 (-3.94%)
GE   100.85 (-1.51%)
DIS   87.91 (+0.10%)
AMC   4.50 (-2.81%)
PFE   37.97 (+2.59%)
PYPL   61.96 (-0.15%)
NFLX   394.16 (+0.30%)
QQQ   347.72 (-0.65%)
AAPL   178.56 (+0.71%)
MSFT   329.60 (-0.49%)
META   262.38 (-0.05%)
GOOGL   122.82 (-0.69%)
AMZN   119.97 (-1.39%)
TSLA   199.33 (-0.91%)
NVDA   382.94 (-4.53%)
NIO   7.41 (+0.00%)
BABA   79.40 (+0.93%)
AMD   119.67 (-4.47%)
T   15.78 (+0.90%)
F   12.03 (-4.45%)
MU   68.29 (-4.74%)
CGC   0.82 (-3.94%)
GE   100.85 (-1.51%)
DIS   87.91 (+0.10%)
AMC   4.50 (-2.81%)
PFE   37.97 (+2.59%)
PYPL   61.96 (-0.15%)
NFLX   394.16 (+0.30%)
QQQ   347.72 (-0.65%)
AAPL   178.56 (+0.71%)
MSFT   329.60 (-0.49%)
META   262.38 (-0.05%)
GOOGL   122.82 (-0.69%)
AMZN   119.97 (-1.39%)
TSLA   199.33 (-0.91%)
NVDA   382.94 (-4.53%)
NIO   7.41 (+0.00%)
BABA   79.40 (+0.93%)
AMD   119.67 (-4.47%)
T   15.78 (+0.90%)
F   12.03 (-4.45%)
MU   68.29 (-4.74%)
CGC   0.82 (-3.94%)
GE   100.85 (-1.51%)
DIS   87.91 (+0.10%)
AMC   4.50 (-2.81%)
PFE   37.97 (+2.59%)
PYPL   61.96 (-0.15%)
NFLX   394.16 (+0.30%)
QQQ   347.72 (-0.65%)
AAPL   178.56 (+0.71%)
MSFT   329.60 (-0.49%)
META   262.38 (-0.05%)
GOOGL   122.82 (-0.69%)
AMZN   119.97 (-1.39%)
TSLA   199.33 (-0.91%)
NVDA   382.94 (-4.53%)
NIO   7.41 (+0.00%)
BABA   79.40 (+0.93%)
AMD   119.67 (-4.47%)
T   15.78 (+0.90%)
F   12.03 (-4.45%)
MU   68.29 (-4.74%)
CGC   0.82 (-3.94%)
GE   100.85 (-1.51%)
DIS   87.91 (+0.10%)
AMC   4.50 (-2.81%)
PFE   37.97 (+2.59%)
PYPL   61.96 (-0.15%)
NFLX   394.16 (+0.30%)
NASDAQ:RETA

Reata Pharmaceuticals (RETA) Stock Forecast, Price & News

$89.14
-0.56 (-0.62%)
(As of 03:10 PM ET)
Compare
Today's Range
$87.82
$90.98
50-Day Range
$79.22
$105.37
52-Week Range
$18.47
$106.69
Volume
335,781 shs
Average Volume
1.22 million shs
Market Capitalization
$3.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$99.89

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
12.5% Upside
$99.89 Price Target
Short Interest
Bearish
17.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.21mentions of Reata Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$12.19 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($10.31) to ($4.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

423rd out of 1,006 stocks

Pharmaceutical Preparations Industry

200th out of 492 stocks


RETA stock logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

Reata Pharmaceuticals (RETA) Gets a Buy from Goldman Sachs
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
Stifel Nicolaus Remains a Buy on Reata Pharmaceuticals (RETA)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
8-K: REATA PHARMACEUTICALS INC
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings
5/10/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$99.89
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+13.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-311,900,000.00
Net Margins
-9,897.91%
Pretax Margin
-23,662.79%

Debt

Sales & Book Value

Annual Sales
$2.22 million
Book Value
($3.48) per share

Miscellaneous

Free Float
26,774,000
Market Cap
$3.31 billion
Optionable
Optionable
Beta
1.53

Social Links


Key Executives

  • J. Warren Huff
    Chairman & Chief Executive Officer
  • Manmeet Singh Soni
    President, Chief Operating & Financial Officer
  • W. Christian Wigley
    Chief Scientific Officer & Senior Vice President
  • Samina Khan
    Chief Medical Officer & Senior Vice President
  • Dakota Gallivan
    VP, Chief Healthcare & Compliance Officer













RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RETA shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2023?

7 equities research analysts have issued twelve-month target prices for Reata Pharmaceuticals' shares. Their RETA share price forecasts range from $75.00 to $120.00. On average, they predict the company's share price to reach $99.89 in the next year. This suggests a possible upside of 13.3% from the stock's current price.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How have RETA shares performed in 2023?

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 132.2% and is now trading at $88.20.
View the best growth stocks for 2023 here
.

When is Reata Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our RETA earnings forecast
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($3.14) earnings per share for the quarter, missing analysts' consensus estimates of ($2.34) by $0.80. The company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.73 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 922.50% and a negative net margin of 9,897.91%.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.02%), Perceptive Advisors LLC (5.91%), First Light Asset Management LLC (4.32%), Deutsche Bank AG (4.07%), Wellington Management Group LLP (3.87%) and State Street Corp (1.72%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff.
View institutional ownership trends
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $88.20.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $3.31 billion and generates $2.22 million in revenue each year.

How many employees does Reata Pharmaceuticals have?

The company employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -